MedTrace Logo

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02588105 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-09-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents. The study will also collect some initial information about how effective it is.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

AZD0156

All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.

DRUG

Olaparib

Module 1 combination with olaparib

DRUG

irinotecan

Module 2 combination with irinotecan/FOLFIRI

DRUG

Fluorouracil

Module 2 combination with irinotecan/FOLFIRI

DRUG

Folinic Acid

Module 2 combination with irinotecan/FOLFIRI

Sponsors & Collaborators

Principal Investigators

  • Matthew Krebs, BMedSci, BM, BS, PhD, MRCP · The Christie Hospital, Manchester, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-10
Primary Completion
2019-09-13
Completion
2022-07-26

Countries

  • United States
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588105 on ClinicalTrials.gov